Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus platinum-doublet chemotherapy for first-line metastatic non-small cell lung cancer
NL-OMON45036Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Denosumab + standard chemotherapy with Placebo + standard chemotherapy (2 arms). Primary endpoint: Overall survival. Started Mar 2014; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45036.